| Literature DB >> 28924876 |
Helena Pópulo1,2, Bruno Nunes1,2,3, Cristina Sampaio1,2, Rui Batista1,2,4, Marta Teixeira Pinto1,2, Tiago B Gaspar1,2, Leandro Miranda-Alves1,2,3, Ren-Zhi Cai5,6, Xian Yang Zhang5,6, Andrew V Schally5,6,7, Manuel Sobrinho-Simões1,2,8,9, Paula Soares10,11,12.
Abstract
Growth hormone-releasing hormone (GHRH) is a peptide hormone secreted by the hypothalamus that regulates the synthesis and secretion of growth hormone (GH) in the pituitary. The extra-hypothalamic GHRH and its cognate receptors (GHRHR and splice variants) play a mitogenic role by stimulating cell proliferation and preventing apoptotic cell death. It is well established that GHRH antagonists inhibit the growth, tumorigenicity, and metastasis of various human malignancies. In this work, we studied the effect of two new GHRH antagonists, MIA602 and MIA690, on thyroid cancer. We studied the effect of MIA602 and MIA690 on thyroid cancer in vitro, using human thyroid cancer cell lines, and in vivo, using chicken embryo chorioallantoic membrane (CAM) assays. We found that mRNA for GHRH and GHRH receptor is expressed in thyroid cell lines and in samples of thyroid tumors. Immunohistochemistry confirmed the expression of GHRHR protein in specimens of thyroid tumor. We observed that GHRH antagonists inhibited the growth and increased apoptosis of thyroid cancer cells. In vivo, the antagonists inhibited growth and angiogenesis of engrafted thyroid tumors. Our results suggest that GHRH expression may play a role in growth of thyroid cancer and that GHRH antagonists can be a therapeutic option for thyroid cancer patients.Entities:
Keywords: GHRH antagonists; Growth hormone-releasing hormone; Hypothalamic hormone; Thyroid cancer; mRNA for GHRH; mRNA for GHRH receptors
Mesh：
Substances：
Year: 2017 PMID： 28924876 DOI： 10.1007/s12672-017-0307-4
Source DB: PubMed Journal: Horm Cancer ISSN： 1868-8497 Impact factor: 3.869